Nature Reviews Rheumatology - Table of Contents alert Volume 9 Issue 9

Advertisement
Frontiers in Internal Medicine is sending out a call to all active researchers and internal medicine experts to help us build a dynamic, highly regarded editorial board! We're currently looking for a Specialist Chief Editor for Chronic Pain Research. Find out more about this and how you can apply for our specialist subject sections here
TABLE OF CONTENTS
September 2013 Volume 9 Number 9
Impact Factor 9.745 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Vaccinations in juvenile chronic inflammatory diseases: an update Clovis A. Silva, Nadia E. Aikawa & Eloisa Bonfa
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Drug therapy: Methotrexate normalizes folate pathway genes in RA Published online: 13 August 2013 p503 | doi:10.1038/nrrheum.2013.127 PDF Therapy: New mechanisms of IVIg Published online: 30 July 2013 p504 | doi:10.1038/nrrheum.2013.119 PDF Inflammation: Fetal bone growth directly and locally impaired by IL-6 Published online: 06 August 2013 p505 | doi:10.1038/nrrheum.2013.124 PDF Development: EGR1 is a key factor in tendon development and healing Published online: 13 August 2013 p505 | doi:10.1038/nrrheum.2013.125 PDF Rheumatoid arthritis: Assessment of CVD in patients with RA by strain imaging Published online: 06 August 2013 p506 | doi:10.1038/nrrheum.2013.117 PDF Crystal arthritis: Intensive urate-lowering therapy improves structural joint damage in patients with tophaceous gout Published online: 30 July 2013 p506 | doi:10.1038/nrrheum.2013.120 PDF IN BRIEF Rheumatoid arthritis: Early changes in MRI findings predict progression of damage | Osteoarthritis: Loss of cartilage in least active and most active patients | Risk factors: Parity in young women associates with ACPA-negative RA PDF Rheumatology EVENT Pan Arab Rheumatology 2014 14.01.14 Dubai More science events from
NEWS AND VIEWS		Top
Spondyloarthritis: Treat-to-target in spondyloarthritis—do we have a plan? Walter P. Maksymowych Published online: 06 August 2013 p507 | doi:10.1038/nrrheum.2013.123 Clinicians now have the therapies and outcome tools to implement treat-to-target strategies aimed at achieving and maintaining adequate function and control of symptoms in spondyloarthritis and psoriatic arthritis. However, validation of surrogate markers of structural progression is a prerequisite for treat-to-target strategies aimed at improving long-term outcomes such as joint damage. Full Text | PDF
Bone diseases: Incident fractures during treatment for osteoporosis Peter Vestergaard Published online: 13 August 2013 p508 | doi:10.1038/nrrheum.2013.122 An incident fracture sustained during treatment for osteoporosis does not necessarily represent treatment failure, an outcome that was redefined in 2012. Predictors of the new definition have now been reported and include ≥2 falls within the past year. Preventing fractures in the most at-risk patients, however, requires improved management strategies. Full Text | PDF
Rheumatoid arthritis: Triple therapy or etanercept after methotrexate failure in RA? Ronald F. van Vollenhoven & Katerina Chatzidionysiou Published online: 30 July 2013 p510 | doi:10.1038/nrrheum.2013.118 Since the 1990s, patients with rheumatoid arthritis have been treated with at least one DMARD. Methotrexate, which is usually the first-line treatment, elicits good or even excellent clinical results in 20–30% of patients—but in most patients it does not. Thus, an important question is what to do after methotrexate failure. Full Text | PDF
REVIEWS		Top
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm Jamie Robertson, Mike J. Peters, Iain B. McInnes & Naveed Sattar Published online: 18 June 2013 p513 | doi:10.1038/nrrheum.2013.91 Despite having increased cardiovascular risk, patients with rheumatoid arthritis (RA) often have low serum cholesterol levels. In this Review, the authors discuss this putative 'lipid paradox', highlighting the relationships of inflammation and anti-inflammatory therapy with lipid profiles in RA. Abstract | Full Text | PDF
Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy Kevin L. Winthrop & Michael Iseman Published online: 25 June 2013 p524 | doi:10.1038/nrrheum.2013.82 Prevention and recognition of mycobacterial disease is of increasing importance to the practicing rheumatologist. Tuberculosis remains a well-known problem for patients and clinicians wishing to use immunosuppressive therapies. Less well recognized, and yet perhaps more important to consider in this context, is nontuberculous mycobacterial disease. Epidemiological data and mechanistic explanations for the increased risk of mycobacterial infection in patients with RA are reviewed herein, and appropriate strategies to prevent and manage these comorbidities are outlined. Abstract | Full Text | PDF
Vaccinations in juvenile chronic inflammatory diseases: an update Clovis A. Silva, Nadia E. Aikawa & Eloisa Bonfa Published online: 02 July 2013 p532 | doi:10.1038/nrrheum.2013.95 Vaccinating children with underlying rheumatic diseases is important to reduce their risk of acquiring infectious diseases. These vaccines are safe to use in this patient group, with the exceptions of profoundly immunosuppressed pateints or those with malevonate kinase deficiency. Some vaccines also induce lower than normal immune responses in these children. Abstract | Full Text | PDF
Advances in understanding the pathogenesis of primary Sjögren's syndrome Gaetane Nocturne & Xavier Mariette Published online: 16 July 2013 p544 | doi:10.1038/nrrheum.2013.110 In the past decade, knowledge of the pathogenesis of primary Sjögren's syndrome and the lymphomagenesis associated with this disease has advanced considerably. This Review summarizes our current understanding of these processes, highlighting the importance of crosstalk between the innate and adaptive immune systems. Abstract | Full Text | PDF
PERSPECTIVES		Top
TIMELINE Advances from clinical trials in juvenile idiopathic arthritis Daniel J. Lovell, Nicola Ruperto, Edward H. Giannini & Alberto Martini Published online: 09 July 2013 p557 | doi:10.1038/nrrheum.2013.105 Many advances in the treatment of juvenile idiopathic arthritis have been underpinned by the development of organizations such as PRINTO and PRCSG. This Perspectives provides a timeline for these advances, including clinical trial designs and diagnostic criteria essential to performing research in this small group of patients whose age necessitates a cautious approach to treatment. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.